ASP5094

DRUG2 trials

Sponsors

Astellas Pharma Global Development, Inc., Astellas Pharma Inc

Conditions

Rheumatoid Arthritis (RA)

Phase 1

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate

CompletedNCT02698657

Astellas Pharma Global Development, Inc.Rheumatoid Arthritis (RA)

Start: 2016-02-23End: 2017-09-07Updated: 2024-10-31

Phase 2

A Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on Methotrexate

CompletedNCT03257852

Astellas Pharma IncRheumatoid Arthritis (RA)

Start: 2017-09-29End: 2018-10-16Updated: 2024-10-31

Related Papers

ASP5094, a humanized monoclonal antibody against integrin alpha-9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: results from a phase 2a, randomized, double-blind, placebo-controlled trial.

2020-10-2111 citations